In this episode of the Oncology Brothers Podcast, hosts Drs. Rohit and Rahul Gosain welcome Dr. Shernan Holtan from Roswell Park Comprehensive Cancer Center to discuss the recent approval of Axatilimab, a novel monoclonal antibody for the treatment of chronic graft-versus-host disease (GVHD).

Join us as we explore the differences between acute and chronic GVHD, the challenges faced by community oncologists in managing this condition, and the exciting results from the AGAVE-201 study that led to Axatilimab's FDA approval. Dr. Holtan shares insights on the drug's mechanism of action, its dosing regimen, and the importance of patient-reported outcomes in assessing treatment efficacy.

We also delve into the safety profile of Axatilimab, discussing potential side effects, infusion reactions, and the significance of partnering with tertiary care centers for optimal patient management.

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on managing chronic GVHD and improving patient quality of life.

Don't forget to like, subscribe, and check out our other episodes for more discussions on recent approvals and the current standard of care for various malignancies!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]